Vistagen Therapeutics Reports Revenue Growth to $244,000 Amid Increased Operating Losses

Vistagen Therapeutics, Inc. reported its financial results for the three months ending June 30, 2025, revealing a total revenue of $244,000, a significant increase from $84,000 in the same period last year. This growth is attributed to the timing of revenue recognized under the AffaMed Agreement. However, the company continues to face substantial operating losses, with a net loss of $15.1 million for the quarter, compared to a loss of $10.7 million in the prior year. The increase in losses is primarily due to heightened research and development expenses, which rose to $11.7 million from $7.6 million year-over-year, driven largely by costs associated with the ongoing PALISADE Program for its lead product candidate, fasedienol.

As of June 30, 2025, Vistagen's total assets amounted to $68.9 million, down from $84.3 million at the end of the previous fiscal quarter. The decline in assets is largely due to a decrease in cash and cash equivalents, which fell to $49.0 million from $67.1 million. The company’s accumulated deficit has also increased to $422.7 million, reflecting its ongoing investment in product development without generating sufficient revenue to cover operational costs. The company’s cash used in operating activities for the quarter was $18.8 million, up from $10.9 million in the same period last year.

Strategically, Vistagen has made significant advancements in its clinical pipeline, particularly with fasedienol, which is being evaluated for the acute treatment of social anxiety disorder (SAD). The company has reported positive topline results from its PALISADE-2 Phase 3 trial and is currently conducting two additional Phase 3 trials, PALISADE-3 and PALISADE-4, with topline data expected in late 2025 and early 2026, respectively. The FDA has granted Fast Track designation for fasedienol, indicating its potential as a first-in-class treatment for SAD.

Operationally, Vistagen's employee headcount has increased, contributing to the rise in research and development expenses. The company is also exploring additional financing options to support its ongoing clinical trials and operational needs, as it has not yet achieved revenue-generating status from its product candidates. As of the filing date, there is uncertainty regarding the sufficiency of its cash reserves to fund operations beyond the next twelve months, raising concerns about its ability to continue as a going concern.

Looking ahead, Vistagen remains focused on advancing its clinical programs and is actively seeking additional capital through equity sales and strategic partnerships. The company aims to leverage its innovative pherine product candidates to address significant unmet medical needs in mental health and women's health, while also managing its operational costs to navigate the challenges of its current financial landscape.